Episode 320: Impella Update with Drs. Essandoh and Cody

Cardiogenic shock management has shifted significantly with the 2025 American Heart Association and ACC guidelines, which now assign a Class 3 recommendation—indicating no survival benefit—to the intra-aortic balloon pump. In contrast, the Impella device has emerged as a superior mechanical circulatory support option, supported by the DANGER shock trial, which demonstrated a mortality reduction at six months. Cardiac anesthesiologists Dr. Joseph Cody and Dr. Mike Essandoh emphasize the necessity of precise hemodynamic assessment, including the use of cardiac power output and pulmonary artery pulsatility index, to guide treatment. Effective management requires a nuanced approach to unburdening the left ventricle while ensuring adequate right ventricular support. Clinicians must balance the benefits of mechanical unloading against potential complications like limb ischemia and bleeding, particularly when escalating support in patients with acute myocardial infarction or post-cardiotomy shock.